Compare EXAS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXAS | ROIV |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 20.7B |
| IPO Year | 2000 | 2021 |
| Metric | EXAS | ROIV |
|---|---|---|
| Price | $103.89 | $27.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $86.62 | $27.56 |
| AVG Volume (30 Days) | 1.8M | ★ 4.6M |
| Earning Date | 04-30-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,144,000.00 | ★ $29,053,000.00 |
| Revenue This Year | $15.37 | N/A |
| Revenue Next Year | $12.41 | $594.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.88 | $8.73 |
| 52 Week High | $104.02 | $30.33 |
| Indicator | EXAS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 50.92 |
| Support Level | $103.10 | $26.94 |
| Resistance Level | N/A | $27.94 |
| Average True Range (ATR) | 0.31 | 0.96 |
| MACD | -0.03 | -0.36 |
| Stochastic Oscillator | 86.96 | 23.85 |
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.